DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

NUVB Oncology Breakout

?? EN ?? IT ✅ NUVB — Oncology Breakout & Commercial Growth Story IBTROZI FDA Approval Success | Q3 Revenue +100% Beat | TRUST-IV Phase 3 Catalyst | $549M Cash | +111% YTD Performance Nuvation Bio — Approved PK activator…

AGIO

AGIO "From Crisis to Recovery: How Dec 7 + Jan 22 PDUFA Decisions Could Drive +80–120% Upside"

KZIA

KZIA Stock Analysis: Biotech Breakthrough in Triple-Negative Breast Cancer | Kazia Therapeutics ?? EN ?? IT ⚡ KZIA — The Breakthrough Moment Immune-Complete Response (iCR) Achieved | Stage IV Metastatic TNBC | +51% Surge on iCR Announcement Kazia Therapeutics —…

Comparative Catalysts and Trade Ideas

Discover comparative catalyst analysis for biotech stocks. This guide provides real-time trading insights comparing FDA PDUFA timelines, pipeline catalysts, and price targets across multiple small-cap pharmaceutical companies. Comparative Catalyst Report – EBS, RIGL, BNBX, DFDV Comparative Catalyst Report EBS |…

ABEO stock

ABEO Daily Catalyst Report | Merlintrader ?? ?? Daily Catalyst Analysis ABEO | ABEONA THERAPEUTICS +28-33% SPIKE – GENE THERAPY COMMERCIAL LAUNCH INFLECTION November 12, 2025 | Q3 Earnings + FDA J-Code Catalyst Analysis Daily Catalyst Analysis ABEO | ABEONA…

$ONDS stock

BULLISH CASE: +426% revenue growth YoY (Wasp drone orders), strategic acquisitions (Sentrycs Nov 4, Safe Pro Nov 6), defense sector tailwinds, 500 units Wasp scalable a 20,000/month, analyst consensus Strong Buy, PT $7.25